Patents by Inventor Eric H. Holmes

Eric H. Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acids and proteins of a rat ganglioside GM1-specific &agr;1?2fucosyltransferase and uses thereof
    Patent number: 6329170
    Abstract: A rat ganglioside GM1-specific &agr;1→2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM1-specific &agr;1→2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM1-specific &agr;1→2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM1-specific &agr;1→2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM1-specific &agr;1→2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM1-specific &agr;1→2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: December 11, 2001
    Assignee: Northwest Hospital
    Inventors: Eric H. Holmes, Anne L. Sherwood
  • Non-invasive methods to detect prostate cancer
    Patent number: 6200765
    Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.
    Type: Grant
    Filed: May 4, 1998
    Date of Patent: March 13, 2001
    Assignee: Pacific Northwest Cancer Foundation
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, Robert J. Barren, III
  • Detection and quantitation of 8-OH-Adenine using monoclonal antibodies
    Patent number: 6187551
    Abstract: The present invention relates generally to assays for 8-hydroxyadenine (8-OH-Ade) and, more particularly, to improved immunoassays for the detection and quantitation of 8-OH-Ade in biological specimens. The present invention further relates to new monoclonal antibodies directed against 8-OH-Ade for use in the immunoassays.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: February 13, 2001
    Assignee: CytoChem, Inc.
    Inventors: Eric H. Holmes, Thomas G. Greene
  • Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
    Patent number: 6150508
    Abstract: The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM' allows the use of an immunoenzymatic assay for their detection.
    Type: Grant
    Filed: March 18, 1998
    Date of Patent: November 21, 2000
    Assignee: Northwest Biotherapeutics, Inc.
    Inventors: Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, William Thomas Tino
  • Diagnosis of premalignant or malignant conditions of human secretory epithelia
    Patent number: 5403717
    Abstract: A method for diagnostic or prognostic monitoring of premalignant or malignant conditions of human secretory epithelia, particularly colonic epithelia, by determining the extent of expression of a .beta.1-3N-acetylglucosaminyltransferase is described. Associated with the expression of a wide variety of carbohydrate antigens in adenocarcinomas is the induction of .beta.1-3N-acetylglucosaminyltransferase in epithelial cells. This enzyme is not found in normal, healthy adult colonic epithelial cells and thus indicates a novel and potentially sensitive method for screening the disease status of individuals.
    Type: Grant
    Filed: December 10, 1992
    Date of Patent: April 4, 1995
    Assignee: Pacific Northwest Research
    Inventor: Eric H. Holmes
  • Diagnosis of cancerous or precancerous conditions in human secretory epithelia by enzyme activity of .beta.-1-3N-acetylglucosaminyltransferase
    Patent number: 4971905
    Abstract: A method for diagnostic or prognostic monitoring of premalignant or malignant conditions of human secretory epithelia, particularly colonic epithelia, by determining the extent of expression of a .beta.1-3N-acetylglucosaminyltransferase is described. Associated with the expression of a wide variety of carbohydrate antigens in adenocarcinomas is the induction of .beta.1-3N-acetylglucosaminyltransferase in epithelial cells. This enzyme is not found in normal, healthy adult colonic epithelial cells and thus indicates a novel and potentially sensitive method for screening the disease status of individuals.
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: November 20, 1990
    Assignee: Pacific Northwest Research Foundation
    Inventor: Eric H. Holmes